医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

MTTI Receives Chinese Patent for EVATHERA Technology

2022年12月06日 PM08:01
このエントリーをはてなブックマークに追加


 

WEST CHESTER, Pa.

Molecular Targeting Technologies, Inc. (MTTI) announces the issuance of Chinese Patent CN109153641B covering MTTI’s lead radiotherapeutic product, EBTATE™ and others in its EvaThera™ platform. Approval of “Chemical conjugates of Evans blue derivatives and their use as radiotherapeutic and imaging agents” follows issued patents in the US, Europe, Singapore, and Japan this past year.

EBTATE is a new generation of peptide receptor radiotherapeutic drug that has demonstrated potential clinical superiority over standard of care. It selectively targets and binds to somatostatin receptor 2 on neuroendocrine and other tumors, which are then killed by the radionuclide. EvaThera platform products were designed to bind to serum albumin, due to the Evans blue moiety, extending in vivo residence time, enabling lower, less frequent dosing of the radiopharmaceutical and reducing risk of renal injury vs. the current standard of care.

Our recent 3-year follow-up report on a 30-patient, ex-US, EBTATE study showed stable disease with progression-free survival of 43 months after three cycles of EBTATE. EBTATE treatment is effective and less toxic for neuroendocrine tumor patients. *

Chris Pak, MTTI’s President & CEO, commented, “This complements our IP portfolio, further protecting our EvaThera platform.” He added, “We’re continuing to bolster our position in radiotheranostics with planned clinical trials of our two platform products in multiple indications.”

About Molecular Targeting Technologies, Inc. (MTTI)

Molecular Targeting Technologies, Inc., is a privately held, rapidly growing, well financed, clinical-stage biotech company developing next-generation targeted radiotherapeutics and diagnostics for rare cancers. We are committed to building value by acquiring and translating innovative imaging, radiopharmaceutical and theranostics assets to improve human health, reduce healthcare costs and reward stakeholders. MTTI expects to be orchestrating multiple clinical trials in 2023. For more information: www.evathera.com

See* below:

https://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=36701

View source version on businesswire.com: https://www.businesswire.com/news/home/20221206005097/en/

CONTACT

Chris Pak, Email: cpak@mtarget.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • メアリー・ケイ、米国栄養学会の年次総会で植物葉エキスの効能に関する新たな研究結果を発表
  • ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer
  • PHCの遠隔医療システム「Teladoc HEALTH」がシェアメディカルのデジタル聴診デバイス「ネクステート」と接続 ~ 接続機器の拡充により遠隔聴診を実現 ~
  • Latest Clinical Data of InnoCare’s Gunagratinib Presented at 2023 ASCO GI
  • Imricor Collaborates with GE HealthCare in Interventional Cardiac MRI